July 22, 2019

Salarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma

To Begin Trading on Nasdaq Capital Market Today Under Ticker Symbol “SLRX”
Houston, TX – July 22, 2019 – Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius Pharmaceuticals, LLC, has closed its merger with Flex Pharma, Inc.’s wholly owned subsidiary on July 19, 2019. Flex Pharma, Inc. has been renamed and will operate as Salarius Pharmaceuticals, Inc.


Jeremy Feffer LifeSci Advisors, Managing Director
Download PDF